Exagen Analyst Ratings
Exagen Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2022 | 105.88% | BTIG | $10 → $7 | Maintains | Buy |
| 11/15/2022 | 105.88% | Canaccord Genuity | $8 → $7 | Maintains | Buy |
| 05/13/2022 | 400% | Keybanc | $20 → $17 | Maintains | Overweight |
| 03/25/2022 | 488.24% | Keybanc | $30 → $20 | Maintains | Overweight |
| 11/11/2021 | 782.35% | Keybanc | $33 → $30 | Maintains | Overweight |
| 04/15/2021 | 635.29% | Canaccord Genuity | → $25 | Initiates Coverage On | → Buy |
| 03/02/2021 | 870.59% | Keybanc | $32 → $33 | Maintains | Overweight |
| 11/10/2020 | 841.18% | Keybanc | → $32 | Initiates Coverage On | → Overweight |
| 10/08/2020 | 429.41% | BTIG | → $18 | Initiates Coverage On | → Buy |
| 06/02/2020 | 488.24% | Cantor Fitzgerald | $19 → $20 | Assumes | → Overweight |
| 11/13/2019 | 635.29% | Cantor Fitzgerald | $18 → $25 | Maintains | Overweight |
| 10/14/2019 | 429.41% | Cantor Fitzgerald | → $18 | Initiates Coverage On | → Overweight |
| 10/14/2019 | 400% | Cowen & Co. | → $17 | Initiates Coverage On | → Outperform |
| 10/14/2019 | — | William Blair | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 11/17/2022 | 105.88% | BTIG | $10 → $7 | 维护 | 买 |
| 11/15/2022 | 105.88% | 卡纳科特·格纳奇 | $8 → $7 | 维护 | 买 |
| 05/13/2022 | 400% | KeyBanc | $20 → $17 | 维护 | 超重 |
| 03/25/2022 | 488.24% | KeyBanc | $30 → $20 | 维护 | 超重 |
| 11/11/2021 | 782.35% | KeyBanc | $33 → $30 | 维护 | 超重 |
| 04/15/2021 | 635.29% | 卡纳科特·格纳奇 | → $25 | 开始承保 | →购买 |
| 03/02/2021 | 870.59% | KeyBanc | $32 → $33 | 维护 | 超重 |
| 11/10/2020 | 841.18% | KeyBanc | → $32 | 开始承保 | →超重 |
| 10/08/2020 | 429.41% | BTIG | → $18 | 开始承保 | →购买 |
| 06/02/2020 | 488.24% | 康托·菲茨杰拉德 | $19 → $20 | 假设 | →超重 |
| 11/13/2019 | 635.29% | 康托·菲茨杰拉德 | $18 → $25 | 维护 | 超重 |
| 10/14/2019 | 429.41% | 康托·菲茨杰拉德 | → $18 | 开始承保 | →超重 |
| 10/14/2019 | 400% | 考恩公司 | → $17 | 开始承保 | →跑赢大盘 |
| 10/14/2019 | — | 威廉·布莱尔 | 开始承保 | →跑赢大盘 |
What is the target price for Exagen (XGN)?
埃克森美孚的目标价是多少？
The latest price target for Exagen (NASDAQ: XGN) was reported by BTIG on November 17, 2022. The analyst firm set a price target for $7.00 expecting XGN to rise to within 12 months (a possible 105.88% upside). 4 analyst firms have reported ratings in the last year.
北京国际集团于2022年11月17日报道了埃克森美孚(纳斯达克：XGN)的最新目标价。这家分析公司将XGN的目标价设定为7美元，预计XGN将在12个月内上涨至(可能上涨105.88%)。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Exagen (XGN)?
分析师对埃克森美孚的最新评级是多少？
The latest analyst rating for Exagen (NASDAQ: XGN) was provided by BTIG, and Exagen maintained their buy rating.
纳斯达克(Sequoia Capital：XGN)的最新分析师评级由北京国际集团提供，艾克森维持买入评级。
When is the next analyst rating going to be posted or updated for Exagen (XGN)?
Exagen(XGN)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exagen was filed on November 17, 2022 so you should expect the next rating to be made available sometime around November 17, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Exagen的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Exagen的上一次评级是在2022年11月17日提交的，所以你应该预计下一次评级将在2023年11月17日左右提供。
Is the Analyst Rating Exagen (XGN) correct?
分析师评级Exagen(XGN)正确吗？
While ratings are subjective and will change, the latest Exagen (XGN) rating was a maintained with a price target of $10.00 to $7.00. The current price Exagen (XGN) is trading at is $3.40, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Exagen(XGN)评级维持不变，目标价在10.00美元至7.00美元之间。埃克森美孚目前的交易价格为3.40美元，超出了分析师的预测区间。
译文内容由第三方软件翻译。